VISUAL OUTCOMES IN PATIENTS WITH DIABETIC MACULAR EDEMA TREATED WITH DEXAMETHASONE IMPLANT IN ROUTINE CLINICAL PRACTICE/ISHOD VIDNE OSTRINE U BOLESNIKA S DIJABETICKIM MAKULARNIM EDEMOM LIJECENIM IMPLANTATOM DEKSAMETAZONA U RUTINSKOJ KLINICKOJ PRAKSI
The aim was to evaluate visual outcomes of the real-life usage of dexamethasone (DEX) implants in diabetic macular edema (DME) patients and evaluate the possible additional visual acuity (VA) gain with combined treatment. We retrospectively reviewed medical records of DME patients treated with DEX i...
Gespeichert in:
| Veröffentlicht in: | Acta clinica Croatica (Tisak) 2021-12, Vol.60 (4), p.602 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 4 |
| container_start_page | 602 |
| container_title | Acta clinica Croatica (Tisak) |
| container_volume | 60 |
| creator | Urbancic, Mojca Topcic, Ivana Gardasevic Matovic, Katja |
| description | The aim was to evaluate visual outcomes of the real-life usage of dexamethasone (DEX) implants in diabetic macular edema (DME) patients and evaluate the possible additional visual acuity (VA) gain with combined treatment. We retrospectively reviewed medical records of DME patients treated with DEX implants. The mean best-corrected visual acuity (BCVA) and mean central retinal thickness (CRT) at baseline and one year were compared. BCVA improved from 58.4[+ or -]14.9 letters at baseline to 62.4[+ or -]14.5 letters at one-year evaluation (p=0.002). The mean change in BCVA was 5.2[+ or -]11.1 letters. CRT decreased from 485.7[+ or -]146.3 [micro]m at baseline to 391.5[+ or -]129.0 [micro]m at one year (p |
| doi_str_mv | 10.20471/acc.2021.60.04.06 |
| format | Article |
| fullrecord | <record><control><sourceid>gale</sourceid><recordid>TN_cdi_gale_infotracmisc_A703278099</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A703278099</galeid><sourcerecordid>A703278099</sourcerecordid><originalsourceid>FETCH-LOGICAL-g679-204d480420862d37fd452ad0382d5aac484844bacb84aa988ac4994b5b2c10763</originalsourceid><addsrcrecordid>eNptkDtPwzAUhTOARHn8ASZLzEmdxEmc0U0McfNwFbsFsVRuklZFfUiUP8_GNe3AgDz4-vj4fEd2nEcfewEmiT82XQdT4Hsx9jDxcHzljHAYhW5K4vjGuT2dPjCc_SgaOd8LoeasQnKuM1lzhUSDZkwL3miFXoUuUC7YhGuRoZpl84q1iOe8Zki3nGmeXzz8jdVcF0zJhiNRzyrWaBvVQq4AKatEIzLgzFqWQRgfC1XIHC1EDrdS6da65mgiK64aUTKkADw9k0tRA7y08AZGy5c1qsSUZ9wKFx7ToOa8VLYKe5cNg8DW8lUpp6j8rWAn6FAqce9cr83uNDxc9jtHP3OdFW4lX2xVdxMnqQs_2hOKSYBpHPRhsu5JFJgehzToI2M6QmGRlelWlBiTUgpSmpJVtAo6HydxeOc8nWM3Zjcst4f18evTdPvtqVuyBIdBQnGagsv7xwWrH_bb7ngY1lvQ_zz4AQZMhSg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>VISUAL OUTCOMES IN PATIENTS WITH DIABETIC MACULAR EDEMA TREATED WITH DEXAMETHASONE IMPLANT IN ROUTINE CLINICAL PRACTICE/ISHOD VIDNE OSTRINE U BOLESNIKA S DIJABETICKIM MAKULARNIM EDEMOM LIJECENIM IMPLANTATOM DEKSAMETAZONA U RUTINSKOJ KLINICKOJ PRAKSI</title><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Urbancic, Mojca ; Topcic, Ivana Gardasevic ; Matovic, Katja</creator><creatorcontrib>Urbancic, Mojca ; Topcic, Ivana Gardasevic ; Matovic, Katja</creatorcontrib><description>The aim was to evaluate visual outcomes of the real-life usage of dexamethasone (DEX) implants in diabetic macular edema (DME) patients and evaluate the possible additional visual acuity (VA) gain with combined treatment. We retrospectively reviewed medical records of DME patients treated with DEX implants. The mean best-corrected visual acuity (BCVA) and mean central retinal thickness (CRT) at baseline and one year were compared. BCVA improved from 58.4[+ or -]14.9 letters at baseline to 62.4[+ or -]14.5 letters at one-year evaluation (p=0.002). The mean change in BCVA was 5.2[+ or -]11.1 letters. CRT decreased from 485.7[+ or -]146.3 [micro]m at baseline to 391.5[+ or -]129.0 [micro]m at one year (p<0.001). The mean change in CRT was -89.6[+ or -]143.3 [micro]m. Patients received a mean of 2.0[+ or -]0.7 DEX implants. Study eyes were also divided into a group receiving DEX implant monotherapy and a group receiving DEX implant and vascular endothelial growth factor inhibitor (anti-VEGF) therapy. Changes in BCVA and CRT and the number of DEX implant injections were compared between the two groups. No difference in VA gain was found between the eyes receiving monotherapy and the eyes receiving combined treatment. In conclusion, DEX implant therapy was effective in gaining vision in DME patients. No additional VA gain was achieved with combined treatment. Key words: Diabetic macular edema; Dexamethasone implant; Routine clinical practice Cilj je bio procijeniti ishod vidne ostrine (VA) uz primjenu implantata deksametazona (DEX) u stvarnom zivotu kod bolesnika s dijabetickim makularnim edemom (DME) te moguce dodatno poboljsanje VA uz kombinirano lijecenje. Proveden je retrospektivni pregled medicinske dokumentacije bolesnika lijecenih implantatom DEX zbog DME. Usporedivane su srednje vrijednosti najbolje korigirane vidne ostrine (BCVA) i srednje vrijednosti centralne debljine mreznice (CRT) na pocetku i nakon godinu dana. BCVA se poboljsala s 58,4[+ or -]14,9 slova u pocetnoj procjeni na 62,4[+ or -]14,5 slova pri procjeni nakon godinu dana (p=0,002). Srednja promjena BCVA iznosila je 5,2[+ or -]11,1 slova. CRT se smanjio s 485,7[+ or -]146,3 [micro]m na pocetnoj razini na 391,5[+ or -]129,0 [micro]m nakon godinu dana (p<0,001). Srednja promjena CRT bila je -89,6[+ or -]143,3 [micro]m. Bolesnici su primili u prosjeku 2,0[+ or -]0,7 implantata DEX. Oci su podijeljene u skupinu koja je primala monoterapiju implantatom DEX i skupinu koja je primala kombinaciju implantata DEX i blokatora vaskularnog endotelnog faktora rasta (anti-VEGF). Promjene u BCVA i CRT te broj injekcija implantata DEX usporedene su izmedu dviju skupina. Nije utvrdena razlika u poboljsanju VA izmedu dviju skupina. Zakljuceno je da je implantat DEX bio ucinkovit u poboljsanju vida kod bolesnika s DME. Kombiniranim lijecenjem nije postignuto dodatno poboljsanje VA. Kljucne rijeci: Dijabeticki makularni edem; Deksametazonski implantat; Rutinska klinicka praksa</description><identifier>ISSN: 0353-9466</identifier><identifier>DOI: 10.20471/acc.2021.60.04.06</identifier><language>eng</language><publisher>Klinicki bolnicki centar Sestre milosrdnice</publisher><subject>Causes of ; Dexamethasone ; Diabetic retinopathy ; Dosage and administration ; Drug therapy ; Eye diseases ; Patient outcomes</subject><ispartof>Acta clinica Croatica (Tisak), 2021-12, Vol.60 (4), p.602</ispartof><rights>COPYRIGHT 2021 Klinicki bolnicki centar Sestre milosrdnice</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,860,27903,27904</link.rule.ids></links><search><creatorcontrib>Urbancic, Mojca</creatorcontrib><creatorcontrib>Topcic, Ivana Gardasevic</creatorcontrib><creatorcontrib>Matovic, Katja</creatorcontrib><title>VISUAL OUTCOMES IN PATIENTS WITH DIABETIC MACULAR EDEMA TREATED WITH DEXAMETHASONE IMPLANT IN ROUTINE CLINICAL PRACTICE/ISHOD VIDNE OSTRINE U BOLESNIKA S DIJABETICKIM MAKULARNIM EDEMOM LIJECENIM IMPLANTATOM DEKSAMETAZONA U RUTINSKOJ KLINICKOJ PRAKSI</title><title>Acta clinica Croatica (Tisak)</title><description>The aim was to evaluate visual outcomes of the real-life usage of dexamethasone (DEX) implants in diabetic macular edema (DME) patients and evaluate the possible additional visual acuity (VA) gain with combined treatment. We retrospectively reviewed medical records of DME patients treated with DEX implants. The mean best-corrected visual acuity (BCVA) and mean central retinal thickness (CRT) at baseline and one year were compared. BCVA improved from 58.4[+ or -]14.9 letters at baseline to 62.4[+ or -]14.5 letters at one-year evaluation (p=0.002). The mean change in BCVA was 5.2[+ or -]11.1 letters. CRT decreased from 485.7[+ or -]146.3 [micro]m at baseline to 391.5[+ or -]129.0 [micro]m at one year (p<0.001). The mean change in CRT was -89.6[+ or -]143.3 [micro]m. Patients received a mean of 2.0[+ or -]0.7 DEX implants. Study eyes were also divided into a group receiving DEX implant monotherapy and a group receiving DEX implant and vascular endothelial growth factor inhibitor (anti-VEGF) therapy. Changes in BCVA and CRT and the number of DEX implant injections were compared between the two groups. No difference in VA gain was found between the eyes receiving monotherapy and the eyes receiving combined treatment. In conclusion, DEX implant therapy was effective in gaining vision in DME patients. No additional VA gain was achieved with combined treatment. Key words: Diabetic macular edema; Dexamethasone implant; Routine clinical practice Cilj je bio procijeniti ishod vidne ostrine (VA) uz primjenu implantata deksametazona (DEX) u stvarnom zivotu kod bolesnika s dijabetickim makularnim edemom (DME) te moguce dodatno poboljsanje VA uz kombinirano lijecenje. Proveden je retrospektivni pregled medicinske dokumentacije bolesnika lijecenih implantatom DEX zbog DME. Usporedivane su srednje vrijednosti najbolje korigirane vidne ostrine (BCVA) i srednje vrijednosti centralne debljine mreznice (CRT) na pocetku i nakon godinu dana. BCVA se poboljsala s 58,4[+ or -]14,9 slova u pocetnoj procjeni na 62,4[+ or -]14,5 slova pri procjeni nakon godinu dana (p=0,002). Srednja promjena BCVA iznosila je 5,2[+ or -]11,1 slova. CRT se smanjio s 485,7[+ or -]146,3 [micro]m na pocetnoj razini na 391,5[+ or -]129,0 [micro]m nakon godinu dana (p<0,001). Srednja promjena CRT bila je -89,6[+ or -]143,3 [micro]m. Bolesnici su primili u prosjeku 2,0[+ or -]0,7 implantata DEX. Oci su podijeljene u skupinu koja je primala monoterapiju implantatom DEX i skupinu koja je primala kombinaciju implantata DEX i blokatora vaskularnog endotelnog faktora rasta (anti-VEGF). Promjene u BCVA i CRT te broj injekcija implantata DEX usporedene su izmedu dviju skupina. Nije utvrdena razlika u poboljsanju VA izmedu dviju skupina. Zakljuceno je da je implantat DEX bio ucinkovit u poboljsanju vida kod bolesnika s DME. Kombiniranim lijecenjem nije postignuto dodatno poboljsanje VA. Kljucne rijeci: Dijabeticki makularni edem; Deksametazonski implantat; Rutinska klinicka praksa</description><subject>Causes of</subject><subject>Dexamethasone</subject><subject>Diabetic retinopathy</subject><subject>Dosage and administration</subject><subject>Drug therapy</subject><subject>Eye diseases</subject><subject>Patient outcomes</subject><issn>0353-9466</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid/><recordid>eNptkDtPwzAUhTOARHn8ASZLzEmdxEmc0U0McfNwFbsFsVRuklZFfUiUP8_GNe3AgDz4-vj4fEd2nEcfewEmiT82XQdT4Hsx9jDxcHzljHAYhW5K4vjGuT2dPjCc_SgaOd8LoeasQnKuM1lzhUSDZkwL3miFXoUuUC7YhGuRoZpl84q1iOe8Zki3nGmeXzz8jdVcF0zJhiNRzyrWaBvVQq4AKatEIzLgzFqWQRgfC1XIHC1EDrdS6da65mgiK64aUTKkADw9k0tRA7y08AZGy5c1qsSUZ9wKFx7ToOa8VLYKe5cNg8DW8lUpp6j8rWAn6FAqce9cr83uNDxc9jtHP3OdFW4lX2xVdxMnqQs_2hOKSYBpHPRhsu5JFJgehzToI2M6QmGRlelWlBiTUgpSmpJVtAo6HydxeOc8nWM3Zjcst4f18evTdPvtqVuyBIdBQnGagsv7xwWrH_bb7ngY1lvQ_zz4AQZMhSg</recordid><startdate>20211201</startdate><enddate>20211201</enddate><creator>Urbancic, Mojca</creator><creator>Topcic, Ivana Gardasevic</creator><creator>Matovic, Katja</creator><general>Klinicki bolnicki centar Sestre milosrdnice</general><scope/></search><sort><creationdate>20211201</creationdate><title>VISUAL OUTCOMES IN PATIENTS WITH DIABETIC MACULAR EDEMA TREATED WITH DEXAMETHASONE IMPLANT IN ROUTINE CLINICAL PRACTICE/ISHOD VIDNE OSTRINE U BOLESNIKA S DIJABETICKIM MAKULARNIM EDEMOM LIJECENIM IMPLANTATOM DEKSAMETAZONA U RUTINSKOJ KLINICKOJ PRAKSI</title><author>Urbancic, Mojca ; Topcic, Ivana Gardasevic ; Matovic, Katja</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-g679-204d480420862d37fd452ad0382d5aac484844bacb84aa988ac4994b5b2c10763</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Causes of</topic><topic>Dexamethasone</topic><topic>Diabetic retinopathy</topic><topic>Dosage and administration</topic><topic>Drug therapy</topic><topic>Eye diseases</topic><topic>Patient outcomes</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Urbancic, Mojca</creatorcontrib><creatorcontrib>Topcic, Ivana Gardasevic</creatorcontrib><creatorcontrib>Matovic, Katja</creatorcontrib><jtitle>Acta clinica Croatica (Tisak)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Urbancic, Mojca</au><au>Topcic, Ivana Gardasevic</au><au>Matovic, Katja</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>VISUAL OUTCOMES IN PATIENTS WITH DIABETIC MACULAR EDEMA TREATED WITH DEXAMETHASONE IMPLANT IN ROUTINE CLINICAL PRACTICE/ISHOD VIDNE OSTRINE U BOLESNIKA S DIJABETICKIM MAKULARNIM EDEMOM LIJECENIM IMPLANTATOM DEKSAMETAZONA U RUTINSKOJ KLINICKOJ PRAKSI</atitle><jtitle>Acta clinica Croatica (Tisak)</jtitle><date>2021-12-01</date><risdate>2021</risdate><volume>60</volume><issue>4</issue><spage>602</spage><pages>602-</pages><issn>0353-9466</issn><abstract>The aim was to evaluate visual outcomes of the real-life usage of dexamethasone (DEX) implants in diabetic macular edema (DME) patients and evaluate the possible additional visual acuity (VA) gain with combined treatment. We retrospectively reviewed medical records of DME patients treated with DEX implants. The mean best-corrected visual acuity (BCVA) and mean central retinal thickness (CRT) at baseline and one year were compared. BCVA improved from 58.4[+ or -]14.9 letters at baseline to 62.4[+ or -]14.5 letters at one-year evaluation (p=0.002). The mean change in BCVA was 5.2[+ or -]11.1 letters. CRT decreased from 485.7[+ or -]146.3 [micro]m at baseline to 391.5[+ or -]129.0 [micro]m at one year (p<0.001). The mean change in CRT was -89.6[+ or -]143.3 [micro]m. Patients received a mean of 2.0[+ or -]0.7 DEX implants. Study eyes were also divided into a group receiving DEX implant monotherapy and a group receiving DEX implant and vascular endothelial growth factor inhibitor (anti-VEGF) therapy. Changes in BCVA and CRT and the number of DEX implant injections were compared between the two groups. No difference in VA gain was found between the eyes receiving monotherapy and the eyes receiving combined treatment. In conclusion, DEX implant therapy was effective in gaining vision in DME patients. No additional VA gain was achieved with combined treatment. Key words: Diabetic macular edema; Dexamethasone implant; Routine clinical practice Cilj je bio procijeniti ishod vidne ostrine (VA) uz primjenu implantata deksametazona (DEX) u stvarnom zivotu kod bolesnika s dijabetickim makularnim edemom (DME) te moguce dodatno poboljsanje VA uz kombinirano lijecenje. Proveden je retrospektivni pregled medicinske dokumentacije bolesnika lijecenih implantatom DEX zbog DME. Usporedivane su srednje vrijednosti najbolje korigirane vidne ostrine (BCVA) i srednje vrijednosti centralne debljine mreznice (CRT) na pocetku i nakon godinu dana. BCVA se poboljsala s 58,4[+ or -]14,9 slova u pocetnoj procjeni na 62,4[+ or -]14,5 slova pri procjeni nakon godinu dana (p=0,002). Srednja promjena BCVA iznosila je 5,2[+ or -]11,1 slova. CRT se smanjio s 485,7[+ or -]146,3 [micro]m na pocetnoj razini na 391,5[+ or -]129,0 [micro]m nakon godinu dana (p<0,001). Srednja promjena CRT bila je -89,6[+ or -]143,3 [micro]m. Bolesnici su primili u prosjeku 2,0[+ or -]0,7 implantata DEX. Oci su podijeljene u skupinu koja je primala monoterapiju implantatom DEX i skupinu koja je primala kombinaciju implantata DEX i blokatora vaskularnog endotelnog faktora rasta (anti-VEGF). Promjene u BCVA i CRT te broj injekcija implantata DEX usporedene su izmedu dviju skupina. Nije utvrdena razlika u poboljsanju VA izmedu dviju skupina. Zakljuceno je da je implantat DEX bio ucinkovit u poboljsanju vida kod bolesnika s DME. Kombiniranim lijecenjem nije postignuto dodatno poboljsanje VA. Kljucne rijeci: Dijabeticki makularni edem; Deksametazonski implantat; Rutinska klinicka praksa</abstract><pub>Klinicki bolnicki centar Sestre milosrdnice</pub><doi>10.20471/acc.2021.60.04.06</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0353-9466 |
| ispartof | Acta clinica Croatica (Tisak), 2021-12, Vol.60 (4), p.602 |
| issn | 0353-9466 |
| language | eng |
| recordid | cdi_gale_infotracmisc_A703278099 |
| source | DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| subjects | Causes of Dexamethasone Diabetic retinopathy Dosage and administration Drug therapy Eye diseases Patient outcomes |
| title | VISUAL OUTCOMES IN PATIENTS WITH DIABETIC MACULAR EDEMA TREATED WITH DEXAMETHASONE IMPLANT IN ROUTINE CLINICAL PRACTICE/ISHOD VIDNE OSTRINE U BOLESNIKA S DIJABETICKIM MAKULARNIM EDEMOM LIJECENIM IMPLANTATOM DEKSAMETAZONA U RUTINSKOJ KLINICKOJ PRAKSI |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-25T13%3A53%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=VISUAL%20OUTCOMES%20IN%20PATIENTS%20WITH%20DIABETIC%20MACULAR%20EDEMA%20TREATED%20WITH%20DEXAMETHASONE%20IMPLANT%20IN%20ROUTINE%20CLINICAL%20PRACTICE/ISHOD%20VIDNE%20OSTRINE%20U%20BOLESNIKA%20S%20DIJABETICKIM%20MAKULARNIM%20EDEMOM%20LIJECENIM%20IMPLANTATOM%20DEKSAMETAZONA%20U%20RUTINSKOJ%20KLINICKOJ%20PRAKSI&rft.jtitle=Acta%20clinica%20Croatica%20(Tisak)&rft.au=Urbancic,%20Mojca&rft.date=2021-12-01&rft.volume=60&rft.issue=4&rft.spage=602&rft.pages=602-&rft.issn=0353-9466&rft_id=info:doi/10.20471/acc.2021.60.04.06&rft_dat=%3Cgale%3EA703278099%3C/gale%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_galeid=A703278099&rfr_iscdi=true |